Stocktoria
Estrella Immunopharma, Inc. ESLA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-19
Estrella Immunopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| R&D expense | $10.2M | $4.1M | $10.5M | — | — |
| Operating income | -$13.1M | -$7.3M | -$11.1M | -$1.6M | — |
| Income tax | $838 | $1,625 | — | $80,648 | $0 |
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996,104 | — |
| EPS (diluted) | $-0.35 | $-0.27 | $-36.35 | — | — |
| Operating cash flow | -$1.8M | -$16.1M | -$1.3M | -$1.0M | — |
| Cash & equivalents | $1.4M | $4.2M | $2.5M | $40,802 | $88,281 |
| Total assets | $3.2M | $4.5M | $3.0M | $9.7M | $45.4M |
| Total liabilities | $13.5M | $180,701 | $9.8M | $2.7M | $1.7M |
| Shareholders' equity | -$10.4M | $4.3M | -$11.7M | -$6.5M | -$1.0M |
Source: SEC EDGAR filings · CIK 0001844417 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.